Affiliations 

  • 1 University of Liverpool, Department of Women's and Children's Health, Liverpool Women's NHS Foundation Trust, Crown Street, Liverpool, L8 7SS, UK
  • 2 Evelina Pharmacy, Guys' & St Thomas' NHS Foundation Trust, London, SE1 7EH, UK
  • 3 Johnson & Johnson, 50-100 Holmers Farm Way, High Wycombe, HP12 4DP, UK
  • 4 ViiV Healthcare, 980 Great West Road Brentford, Middlesex, TW8 9GS, UK
  • 5 Leeds Beckett University, Leeds, LS1 3HE, England, UK
  • 6 Conect4children Stichting, Utrecht, Netherlands
  • 7 French Clinical Research Infrastructure Network (F-CRIN)-PEDSTART, INSERM, University of Tours, University Hospital of Orléans, Orléans, France
Contemp Clin Trials Commun, 2025 Apr;44:101442.
PMID: 40008277 DOI: 10.1016/j.conctc.2025.101442

Abstract

INTRODUCTION: The Collaborative Network for European Clinical Trials for Children (c4c) is a public private partnership with a developed infrastructure across European sites to support the design and conduct of multi-national academic and industry paediatric clinical trials. This paper aims to review the learning points identified during co-development of c4c processes by academic and industry partners.

METHODS: Study metrics were recorded. Learning points were captured during network development, categorized and included in a thematic analysis from which lessons learnt were identified.

RESULTS: 12 trials were supported by sites coordinated at national level and integrated at European level. A total of 9 CDA cycles were completed, resulting in 436 site CDAs signed in a median of 8.11 days. Lessons learnt included the importance of: relationship building by early engagement with partners; reducing misunderstanding by clear communication; flexibility, adaptability and experiential learning which are required for service improvement. Practical actions that infrastructure developers and users can take include operational planning with a view to fostering collaborations across stakeholders, sharing information about different approaches to clinical operations, and raising awareness of the need for explicit work on collaboration, communication, and planning. Traditionally, these activities are repeated for each trial. The use of a persistent network allows the benefits of collaboration to be recycled.

DISCUSSION: Building a successful framework for collaboration allows dedication and determination to carry over from one study to another. The initial investment of time to share assumptions and "state the obvious" by each user will support future trials.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.